SkinMedica® Deepens Commitment to Regenerative Science with Continued Investment in Research and Development Pharmaceutical Investing
Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market Facility Life Science Investing
Lexston Guyana Inc. Enters Into Letter Of Intent To Acquire Strategic Guyana Mineral Claims Life Science Investing
EraNova Produces 50 oz Silver Bar from Silver Surprise Mini-Bulk Sample at Local Atlin Facility Life Science Investing
Axsome Therapeutics to Report Second Quarter 2026 Financial Results on August 10 Life Science Investing
Summit Therapeutics Signs Agreement to Sell Phase III Asset Ridinilazole to Biossil, Inc. Life Science Investing
Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus Life Science Investing
Atrium Therapeutics Announces FDA Clearance of Investigational New Drug Application for ATR 1072 for Treatment of PRKAG2 Syndrome Life Science Investing
Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties Life Science Investing
Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 , a Phase 2-Ready Third-Generation Anti-CD40L Antibody Life Science Investing
FDA Approves LEQEMBI IQLIK® Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease Life Science Investing
